ECSP23081932A - Virus oncolíticos para la expresión modificada del mhc - Google Patents
Virus oncolíticos para la expresión modificada del mhcInfo
- Publication number
- ECSP23081932A ECSP23081932A ECSENADI202381932A ECDI202381932A ECSP23081932A EC SP23081932 A ECSP23081932 A EC SP23081932A EC SENADI202381932 A ECSENADI202381932 A EC SENADI202381932A EC DI202381932 A ECDI202381932 A EC DI202381932A EC SP23081932 A ECSP23081932 A EC SP23081932A
- Authority
- EC
- Ecuador
- Prior art keywords
- oncolytic viruses
- mhc expression
- modified mhc
- viruses
- major histocompatibility
- Prior art date
Links
- 244000309459 oncolytic virus Species 0.000 title abstract 2
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación prevé virus oncolíticos recombinantes con deleciones o inserciones de genes que causan una regulación a la baja del complejo mayor de histocompatibilidad clase I y, alternativamente o aditivamente, en una regulación al alza del complejo mayor de 5 histocompatibilidad clase II También se presentan composiciones inmunológicas y farmacéuticas que comprenden estos virus recombinantes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163182243P | 2021-04-30 | 2021-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP23081932A true ECSP23081932A (es) | 2023-11-30 |
Family
ID=83848828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202381932A ECSP23081932A (es) | 2021-04-30 | 2023-10-26 | Virus oncolíticos para la expresión modificada del mhc |
Country Status (15)
Country | Link |
---|---|
US (2) | US20230263846A1 (es) |
EP (1) | EP4329786A1 (es) |
JP (1) | JP2024516400A (es) |
KR (1) | KR20240004764A (es) |
CN (1) | CN117241813A (es) |
AU (1) | AU2022265689A1 (es) |
BR (1) | BR112023022681A2 (es) |
CA (1) | CA3215344A1 (es) |
CL (1) | CL2023003199A1 (es) |
CO (1) | CO2023014507A2 (es) |
DO (1) | DOP2023000233A (es) |
EC (1) | ECSP23081932A (es) |
IL (1) | IL308018A (es) |
TW (1) | TW202305125A (es) |
WO (1) | WO2022232375A1 (es) |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
IL71275A0 (en) | 1983-03-21 | 1984-06-29 | Sparamedica Ag | Human interleukin-2-and its preparation |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
DK0639186T3 (da) | 1992-04-17 | 1999-12-13 | Abbott Lab | Taxolderivater |
EP0911413A3 (en) | 1992-12-03 | 2000-11-15 | Genzyme Corporation | Minimal adenovirus-based gene therapy vector |
ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
SK282843B6 (sk) | 1993-07-13 | 2002-12-03 | Rhone-Poulenc Rorer S. A. | Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
DE69840426D1 (de) | 1997-11-10 | 2009-02-12 | Strakan Int Ltd | Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AT406376B (de) | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
US6198323B1 (en) | 1999-01-28 | 2001-03-06 | Lucent Technologies Inc. | Flip-flop having gated inverter feedback structure with embedded preset/clear logic |
US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
AR030188A1 (es) | 2000-02-02 | 2003-08-13 | Univ Florida State Res Found | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos |
ES2249430T3 (es) | 2000-03-14 | 2006-04-01 | Bavarian Nordic A/S | Cepa alterada del virus ankara de la vacuna modificado (mva). |
EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
ATE313334T1 (de) | 2000-04-25 | 2006-01-15 | Immunex Corp | Behandlung von tumoren mit photodynamischer therapie |
US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
AU2001272750A1 (en) | 2000-07-21 | 2002-02-13 | Chiba Prefecture | Tumor-specific promoters |
WO2002029088A2 (en) * | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Highly expressible genes |
EP1213025A1 (de) | 2000-12-06 | 2002-06-12 | Laboratoires Serobiologiques(Societe Anonyme) | Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa |
EP1341817A2 (en) | 2000-12-08 | 2003-09-10 | Novo Nordisk A/S | Tff peptides |
WO2002092134A1 (en) | 2001-05-14 | 2002-11-21 | Cell Genesys, Inc. | Lentiviral vectors encoding clotting factors for gene therapy |
JP2003009883A (ja) | 2001-07-05 | 2003-01-14 | Mitsubishi Pharma Corp | マスト細胞の細胞死誘発剤 |
WO2003035683A2 (en) | 2001-10-26 | 2003-05-01 | Uffe Holmskov | Surfactant protein-d and atherosclerosis |
US7368122B1 (en) | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
EP2269619A1 (en) | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
DK1767535T3 (da) | 2002-08-23 | 2010-04-12 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse |
US20040143026A1 (en) | 2002-12-31 | 2004-07-22 | Shah Kishore R. | Bioadhesive hydrophilic composition for treatment of mammalian skin |
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
CN1878793A (zh) | 2003-09-11 | 2006-12-13 | 鉴定医疗有限公司 | 拮抗hmgb1的单克隆抗体 |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
JP4719855B2 (ja) | 2003-12-05 | 2011-07-06 | 国立大学法人北海道大学 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
DK1838341T3 (da) | 2005-01-20 | 2013-11-04 | Isconova Ab | Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid |
US20100016224A1 (en) | 2006-08-25 | 2010-01-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe | Compositions and methods for modulating an immune response |
ES2396376T5 (es) | 2006-08-25 | 2017-05-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sitios intergénicos entre genes conservados en el genoma del virus vaccinia de vaccinia Ankara modificado (MVA) |
EP2415783B1 (en) * | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
GB0702695D0 (en) | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
US8003363B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
CA2963124C (en) | 2007-07-10 | 2019-10-15 | Apogenix Ag | Tnf superfamily collectin fusion proteins |
WO2009111066A1 (en) | 2008-03-06 | 2009-09-11 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
PT2119726E (pt) * | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
US10603351B2 (en) | 2008-08-21 | 2020-03-31 | Turnstone Limited Partnership | Engineered synergistic oncolytic viral symbiosis |
CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
EP2184297A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
CA2709292A1 (en) | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
US9186371B2 (en) | 2010-09-17 | 2015-11-17 | Japan Science And Technology Agency | Inhibitor of HMGB protein-mediated immune response activation, and screening method |
WO2012089225A1 (en) * | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
JP6121910B2 (ja) | 2011-01-04 | 2017-04-26 | シラジェン バイオセラピューティクス インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成 |
CN103732236B (zh) | 2011-08-05 | 2017-09-15 | 新罗杰公司 | 用于生产痘苗病毒的方法和组合物 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2877572B1 (en) | 2012-07-24 | 2018-11-28 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
EP3461491A1 (en) | 2013-04-18 | 2019-04-03 | TILT Biotherapeutics Oy | Enhanced adoptive cell therapy |
CA2917937C (en) * | 2013-07-18 | 2022-11-01 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
PE20160673A1 (es) | 2013-08-22 | 2016-07-21 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Terapias inmuno-oncoliticas |
US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
MA39818A (fr) * | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
US20160060319A1 (en) | 2014-08-27 | 2016-03-03 | Cellivery Therapeutics, Inc. | Development of Protein-Based Biotherapeutics That Induced Osteogenesis for Bone Healing Therapy: Cell-Permeable BMP2 and BMP7 Recombinant Proteins (CP-BMP2 & CP-BMP7), Polynucleotides Encoding the Same and Pro-osteogenic Compositions Comprising the Same |
PT3186281T (pt) | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
CA3203273A1 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
EP3324988B1 (en) | 2015-07-20 | 2021-03-03 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus in combination with immune checkpoint inhibitor, in the treatment of cancer |
US10646524B2 (en) | 2015-09-08 | 2020-05-12 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof |
KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
EP3263181A1 (en) | 2016-06-30 | 2018-01-03 | AVA, Inc. | Stable and safe antiseptic solution comprising chlorhexidine |
US11065286B2 (en) | 2016-09-21 | 2021-07-20 | Stephen H. Thorne | High mobility group box I mutant |
WO2018058258A1 (en) | 2016-09-30 | 2018-04-05 | University Health Network | Recombinant oncolytic viruses for cancer therapy |
WO2018091680A1 (en) * | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
US11185586B2 (en) | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
CA3046961A1 (en) * | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
WO2019055860A1 (en) * | 2017-09-15 | 2019-03-21 | The Texas A&M University System | METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER |
EP3703723A4 (en) * | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
CA3087044A1 (en) | 2018-01-26 | 2019-08-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
AR115069A1 (es) * | 2018-05-02 | 2020-11-25 | David Evans | Virus vacuna quimérico sintético |
CN113271955A (zh) * | 2018-11-06 | 2021-08-17 | 卡利迪生物治疗有限公司 | 用于细胞介导的溶瘤病毒疗法的增强的系统 |
-
2022
- 2022-04-28 TW TW111116203A patent/TW202305125A/zh unknown
- 2022-04-28 CA CA3215344A patent/CA3215344A1/en active Pending
- 2022-04-28 CN CN202280031349.4A patent/CN117241813A/zh active Pending
- 2022-04-28 AU AU2022265689A patent/AU2022265689A1/en active Pending
- 2022-04-28 IL IL308018A patent/IL308018A/en unknown
- 2022-04-28 BR BR112023022681A patent/BR112023022681A2/pt unknown
- 2022-04-28 EP EP22796714.8A patent/EP4329786A1/en active Pending
- 2022-04-28 KR KR1020237041238A patent/KR20240004764A/ko unknown
- 2022-04-28 WO PCT/US2022/026703 patent/WO2022232375A1/en active Application Filing
- 2022-04-28 JP JP2023565513A patent/JP2024516400A/ja active Pending
- 2022-12-13 US US18/080,253 patent/US20230263846A1/en active Pending
-
2023
- 2023-05-24 US US18/322,961 patent/US11963990B2/en active Active
- 2023-10-20 DO DO2023000233A patent/DOP2023000233A/es unknown
- 2023-10-26 EC ECSENADI202381932A patent/ECSP23081932A/es unknown
- 2023-10-26 CO CONC2023/0014507A patent/CO2023014507A2/es unknown
- 2023-10-26 CL CL2023003199A patent/CL2023003199A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4329786A1 (en) | 2024-03-06 |
TW202305125A (zh) | 2023-02-01 |
JP2024516400A (ja) | 2024-04-15 |
US20230338445A1 (en) | 2023-10-26 |
KR20240004764A (ko) | 2024-01-11 |
AU2022265689A1 (en) | 2023-10-19 |
US11963990B2 (en) | 2024-04-23 |
BR112023022681A2 (pt) | 2024-01-23 |
CA3215344A1 (en) | 2022-11-03 |
CN117241813A (zh) | 2023-12-15 |
US20230263846A1 (en) | 2023-08-24 |
WO2022232375A1 (en) | 2022-11-03 |
DOP2023000233A (es) | 2023-12-15 |
CO2023014507A2 (es) | 2023-11-10 |
CL2023003199A1 (es) | 2024-04-05 |
IL308018A (en) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001920A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
CO2019014840A2 (es) | Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett | |
BR112019001737A2 (pt) | expressão de pten-long com vírus oncolíticos | |
ES2150416T3 (es) | Vacuna virica defectiva producida por una linea celular complementada en trans. | |
ES2104556T3 (es) | Peptidos que tienen propiedades inmunologicas de hiv-2. | |
BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
BR112021019120A2 (pt) | Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente | |
PE20211307A1 (es) | ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS | |
BR112023005043A2 (pt) | Vacina contra covid-19 à base de piv5 | |
PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
CL2021002807A1 (es) | Anticuerpos y métodos para el tratamiento de la infección por influenza a | |
AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
ECSP23081932A (es) | Virus oncolíticos para la expresión modificada del mhc | |
CL2022003390A1 (es) | Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2. | |
CO2022017087A2 (es) | Péptidos y métodos para el tratamiento de esclerosis múltiple | |
BRPI0411099A (pt) | composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus | |
AR118881A1 (es) | Composiciones de virus inactivado y formulaciones de vacuna contra el zika | |
CO2019012289A2 (es) | Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar | |
BR112022020298A2 (pt) | Vacinas, adjuvantes e métodos para gerar uma resposta imune | |
PE20230433A1 (es) | Composiciones de virus adenoasociados para restaurar la funcion del gen pah y los metodos de uso de estas | |
AR117877A1 (es) | Rhabdovirus recombinante que codifica ccl21 | |
PE20211656A1 (es) | Moduladores de la expresion de foxp3 | |
CL2019000405A1 (es) | Vacunas virales. | |
CO2022017623A2 (es) | Vacuna recombinante contra covid-19 en vector viral de paramixovirus | |
TW201614163A (en) | A lighting system |